LY 3192767

Drug Profile

LY 3192767

Alternative Names: LY3192767

Latest Information Update: 01 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetes mellitus

Most Recent Events

  • 13 Mar 2017 Phase-I clinical trials in Diabetes mellitus (In volunteers) in Germany (SC) (NCT03025009)
  • 17 Jan 2017 Preclinical trials in Diabetes mellitus in USA (SC) before January 2017
  • 17 Jan 2017 Eli Lilly plans a phase I trial in Healthy volunteers in Germany (SC) (NCT03025009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top